Citations

Clear

114 citation(s) found for "Borah, Bijan J".

Cost-Effectiveness of Anterior and Posterior Surgical Approaches for Cervical Spondylotic Myelopathy: An Economic Evaluation of a Randomized Clinical Trial
Whitmore, Robert G. , Miranda, Stephen P. , Bydon, Mohamad , Dholakia, Ruchita, Moriarty, James P. , Borah, Bijan J. , Kanter, Adam S., Mummaneni, Praveen V. , Bisson, Erica F. , Harrop, James S., Magge, Subu N., Heary, Robert F., Fehlings, Michael G. , Albert, Todd J. , Arnold, Paul M., Riew, Kiehyun Daniel , Steinmetz, Michael P., Benzel, Edward, Wang, Marjorie C., Heller, John G., Ghogawala, Zoher

Mayo Clinic

Neurosurgery | November 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/neu.0000000000004268 | PMID 42975416 Get It

BACKGROUND AND OBJECTIVES: Surgery for cervical spondylotic myelopathy improves quality of life but remains expensive. We conducted a cost-effectiveness analysis of patients treated with anterior cervical diskectomy/fusion (ACDF), posterior cervical decompression/fusion (PCDF), and laminoplasty (LP) in the Cervical Spondylotic Myelopathy Surgical (CSM-S) Trial, a randomized trial comparing surgical approaches for cervical spondylotic myelopathy. METHODS: In the trial, patients were randomized (2:3) to anterior (ACDF) or posterior surgery (LP or PCDF, at surgeon's discretion). A cost-effectiveness analysis was performed from a societal perspective with a 1-year time horizon, including only US patients as-treated. Cumulative costs were estimated using patient data on utilization and lost productivity using a human capital approach. Direct costs were calculated using 2022 Medicare rates for professional fees and cost-to-charge ratios for hospital services. Quality-adjusted life-years (QALYs) were calculated from patient responses to the EuroQol-5-Dimensions instrument at baseline and 3, 6, and 12 months postoperatively. Incremental cost-effectiveness ratio analysis was performed with bootstrapping to address uncertainty. RESULTS: Of 163 total patients enrolled in the CSM-S Trial, 153 from the United States (mean age, 62 years; 80 (52%) female) were included as-treated (ACDF = 61, PCDF = 64, LP = 28) in a cost-effectiveness analysis. Economic data were not available for 9 patients. The remaining 144 patients treated (ACDF = 55, PCDF = 61, LP = 28) had cost data through a 1-year follow-up. Mean hospitalization costs were higher after PCDF than ACDF and LP ($33 410 vs $26 468 vs $25 550; P < .001). Mean total costs were higher after PCDF than ACDF and LP ($62 383 vs $53 074 vs $47 426; P = .017). LP yielded greater QALY gains than ACDF (0.792 vs 0.732; P = .08) and PCDF (0.792 vs 0.698; P = .01). At a willingness-to-pay threshold of $150 000/QALY-gained, the probability that LP was cost-effective compared with PCDF was 99.7% and the probability compared with ACDF was 96%. CONCLUSION: In the CSM-S Trial, LP yielded greater 1-year quality-of-life improvements at lower costs than PCDF and ACDF.
Normothermic Machine Perfusion, Patient-Centered Recovery, and Graft Survival After Donation-After-Circulatory-Death Liver Transplantation
Frasco, Peter E. , Mathur, Amit K, Zhang, Nan , Brennan, Bayley, Jadlowiec, Caroline, Milam, Adam J, Nguyen, Michelle K, Fah, Megan, Patel, Bhavesh M, Bettini, Layne M, Dholakia, Ruchita, Borah, Bijan, Barnhill, Michele , Aqel, Bashar, Jadlowiec, Caroline C. , Bettini, Layne M., Borah, Bijan J. , Barnhill, Michele

Mayo Clinic

Journal of the American College of Surgeons | September 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/xcs.0000000000002226 | PMID 42770976 Get It

Background: Normothermic machine perfusion (NMP) may reduce preservation injury in donation-after-circulatory-death (DCD) liver transplantation, but its association with patient-centered recovery and longer-term graft survival remains uncertain. Study Design: We retrospectively analyzed 306 consecutive adult DCD liver transplant recipients at a single center from January 2019 through December 2022, comparing NMP (n=95) with static cold storage (SCS; n=211). The primary endpoint was days alive and out of hospital at 365 days (DAOH365). Quasi-Poisson regression evaluated factors associated with DAOH365, and Cox regression evaluated graft survival. Propensity-matched and calendar-year sensitivity analyses assessed measured confounding. Results: Median DAOH365 was 357.0 (352.0, 360.0) days with NMP versus 353.0 (336.0, 359.0) with SCS (p<0.001), but preservation strategy was not independently associated with DAOH365 (adjusted rate ratio 1.02; p=0.331). NMP recipients had less early allograft dysfunction (35.8% vs 59.7%; p<0.001), ischemic cholangiopathy (4.2% vs 23.7%; p<0.001), and retransplantation within 2 years (0.0% vs 6.6%; p=0.007). Two-year patient survival did not differ significantly. NMP was associated with improved twoF-year graft survival (HR 2.9, 95% CI 1.23–6.87; p=0.015), an association maintained in propensity-matched and calendar-year sensitivity analyses. Adjusted total 1-year costs did not differ (p=0.512). Conclusions: In this single-center DCD cohort, NMP was associated with superior 2-year graft survival but not independently with DAOH365. These hypothesis-generating findings support multicenter prospective evaluation of NMP using both graft survival and patient-centered recovery endpoints.
Racial and Socioeconomic Factors Associated with Hysterectomy for Uterine Fibroids
Louie, Michelle , Stevens, Maria , Salunke, Juhi , Laughlin-Tommaso, Shannon K., Stewart, Elizabeth A., Stevens, Maria A, Rassier, Sarah L Cohen, Rassier, Sarah L. Cohen , Stewart, Elizabeth A. , Borah, Bijan J.

Mayo Clinic

Journal of Women's Health | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15409996261472992 | PMID 42533477 Get It

Objective: To evaluate the relationship between race and social determinants of health and receipt of hysterectomy versus uterine-preserving fibroid treatment. Methods: A retrospective cohort study using deidentified claims and longitudinal health data from OptumLabs ® Data Warehouse. Patients aged 15–55 years with newly diagnosed fibroids between 2010 and 2023 were included. Menopausal individuals and those with gynecological cancer were excluded. The primary outcome was hysterectomy by any route versus uterine-preserving fibroid surgery within 180 days of fibroid diagnosis. We used logistic regression to assess associations between socioeconomic factors and receipt of hysterectomy after adjusting for pertinent covariates. Results: A total of 73,479 individuals were included; 50,645 received hysterectomy, 22,834 received a uterine-preserving treatment. Race, income, education level, and rurality were independently associated with the probability of hysterectomy. Odds of hysterectomy were lower for all people of color compared with White individuals (Asian odds ratio [OR] 0.61 [95% confidence interval (CI): 0.56–0.66], Black OR: 0.70 [95% CI: 0.67–0.73], and Hispanic OR: 0.90 [95% CI: 0.86–0.95]). Individuals with household income <$40,000, less than high school education, and rural address were more likely to undergo hysterectomy compared with those with income >$124,999 (OR: 1.15, 95% CI: 1.09–1.21), bachelor’s degree or higher (OR: 2.55, 95% CI: 1.78–3.65), and metropolitan address (OR: 1.70, 95% CI: 1.44–2.01). All associations were significant at p < 0.05. Conclusion: People with fewer socioeconomic advantages, such as lower household income, lower educational attainment, and rural address were more likely to receive hysterectomy rather than uterine-preserving fibroid treatment. After controlling for age, surgery year, and socioeconomic factors, people of color were less likely to receive hysterectomy rather than uterine-preserving fibroid treatment.
Financial Comparison of Single- vs 2-Stage Management of Bile Duct Stones
Jorge, Irving, Kandil, Omneya , Huschka, Todd, Joshi, Devendra, Ven Fong, Zhi, Jorge, Irving , Joshi, Devendra, Huschka, Todd , Fong, Zhi Ven , Borah, Bijan J.

Mayo Clinic

JAMA Surgery | June 24, 2026 | Volume: 161 | Issue: 8 | Pages: 846

10.1001/jamasurg.2026.2185 | PMID 42340701 Get It

This economic evaluation assesses the costs, reimbursements, and estimated net operating margin of single- and 2-stage strategies for managing bile duct stone clearance to compare the financial outcomes of both strategies.
The Reality of Benign Prostatic Hyperplasia Surgery Price and Reimbursement Across Top United States Hospitals
Murray, Gillian, Edmonds, Victoria, Borah, Bijan, Kelleher, Dan , Wymer, Kevin , Edmonds, Victoria S. , Borah, Bijan J.

Mayo Clinic

Urology Practice | June 9, 2026 | Volume: 13 | Issue: 5 | Pages: 495-502

10.1097/upj.0000000000001033 | PMID 42262115 Get It

Real-World Health Care Resource Utilization and Economic Burden Among Patients with Idiopathic Pulmonary Fibrosis in Commercially Insured and Medicare Advantage Populations in the United States
Yang, Joseph, Fee, Rebecca, Steffens, Andrea , Le, Lisa, Bui, Bonnie H. , Yang, Joseph , Fee, Rebecca M. , Bui, Bonnie , Borah, Bijan J.

Mayo Clinic

Journal of Health Economics and Outcomes Research | June 3, 2026 | Volume: 13 | Issue: 1 | Pages: No page available

10.36469/001c.161503 | PMID 42254470 Get It

Background: The economic burden associated with idiopathic pulmonary fibrosis (IPF) is not well understood, especially since the approval of antifibrotic medications to treat IPF in 2014. Objective: This study assessed healthcare resource utilization (HCRU) and costs for patients with and without IPF among insured patients in the United States. Methods: This retrospective study used claims data from the Optum Research Database from 01 January 2016 through 31 December 2023. The IPF cohort included patients with at least 2 claims for IPF within 365 days. A comparator cohort was exact matched to the IPF cohort in a 4:1 ratio on demographic characteristics. Follow-up all-cause and respiratory-related HCRU and costs were collected. Outcomes were presented as weighted per-patient per-month (wPPPM) to account for variable follow-up. Descriptive results were reported by cohort, overall, and stratified by insurance type. All-cause and respiratory-related wPPPM costs were modeled using generalized linear models and time to all-cause and respiratory-related inpatient visits were modeled using Cox proportional hazards regression models, adjusted for baseline comorbidities. Results: A total of 7582 patients were included in the IPF cohort; 10.4% were commercially insured and 89.6% insured by Medicare Advantage Prescription Drug (MAPD) plans. The comparator cohort included 30 328 demographically matched controls. Overall, mean all-cause wPPPM counts of HCRU during follow-up were significantly higher in the IPF cohort than the comparator cohort for all categories (all P < .001). Similarly, mean (SD) follow-up all-cause wPPPM total healthcare costs were higher for the IPF cohort than the comparator cohort ($4667 [$8252] vs $1196 [$2114], P < .001). After adjustment, the cost ratio for all-cause total healthcare costs between the IPF and comparator cohorts was 3.4 (95% confidence interval [CI], 3.10-3.64), and patients in the IPF cohort were 2.1 times (95% CI, 1.97-2.15) more likely to be hospitalized for all causes than the comparator cohort. For both HCRU and costs, similar patterns were observed in both the commercial and MAPD populations. Conclusion: Patients with IPF incurred substantially higher HCRU and costs than the demographically matched comparator cohort. Study results suggest the need for treatment options to improve management of IPF and reduce costly HCRU.
Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target Trial
Zehra, Anum , Deng, Yihong , Swarna, Kavya Sindhu, Herrin, Jeph, Polley, Eric C. , Neumiller, Joshua J. , Galindo, R, Umpierrez, Guillermo E. , Ross, Joseph S. , Brito, Juan P., Maron, Bradley A. , Mickelson, Mindy M. , McCoy, Rozalina G., Herrin, Jeph , Galindo, Rodolfo J. , Herrin, Jeph , Galindo, Rodolfo J , Montori, Victor M , Maron, Bradley A , Mickelson, Mindy M , McCoy, Rozalina Grubina , Umpierrez, Guillermo E. , Polley, Eric C , Ross, Joseph S , Deng, Yihong , Neumiller, Joshua J. , Zehra, Anum , Swarna, Kavya, Brito, Juan P. , Montori, Víctor M. , Borah, Bijan J. , McCoy, Rozalina G.

Mayo Clinic

Journal of the American Heart Association | May 14, 2026 | Volume: 15 | Issue: 10 | Pages: No page available

10.1161/jaha.125.046238 | PMID 42132163 Get It

Background SGLT2 (sodium‐glucose cotransporter 2) inhibitors reduce major adverse cardiovascular events (MACE) in type 2 diabetes. However, no direct comparison of individual SGLT2 inhibitor drugs has been conducted, particularly among adults with moderate cardiovascular risk who comprise most people with type 2 diabetes. Methods We used data for commercial, Medicare Advantage, and Medicare fee‐for‐service beneficiaries to emulate a target trial of adults (≥21 years) with type 2 diabetes and moderate cardiovascular risk who started canagliflozin, dapagliflozin, or empagliflozin between 2015 and 2020. We estimated propensity scores using the super learner ensemble method and incorporated them as inverse probability of treatment weights into Cox models, estimating risk of MACE, expanded MACE, and hyperglycemic and hypoglycemic crises through December 31, 2022. Results The weighted cohort, balanced on all baseline covariates, included 137 232 patients (mean age 65.7 years [SD, 8.1], 75.3% non‐Hispanic White, 57.0% male, 81.9% on metformin, 11.4% on glucagon‐like peptide‐1 receptor agonists) starting canagliflozin (N=42 877), dapagliflozin (N=17 871), or empagliflozin (N=7648). The risk of MACE was lower among patients starting empagliflozin versus canagliflozin (hazard ratio [HR], 0.92 [95% CI, 0.87–0.97]), driven by reduced risk of all‐cause mortality (HR, 0.86 [95% CI, 0.80–0.94]). There was no difference in MACE between empagliflozin versus dapagliflozin or dapagliflozin versus canagliflozin therapy. There was no difference in remaining outcomes between the three drugs. Conclusions The 3 most used SGLT2 inhibitor medications demonstrate similar effectiveness on cardiovascular outcomes among patients with type 2 diabetes at moderate cardiovascular risk, with differences between these drugs small in magnitude. Clinicians and health systems should prioritize enhancing access to these cardioprotective therapies.
Medication adherence research: expert perspectives on key HEOR trends for 2026
Ágh, Tamás , Borah, Bijan J. , Vervloet, Marcia , Hiligsmann, Mickaël , Borah, Bijan J

Mayo Clinic

Expert Review of Pharmacoeconomics & Outcomes Research | March 23, 2026 | Volume: 26 | Issue: 4 | Pages: 469-471

10.1080/14737167.2026.2650160 | PMID 41870484 Get It

Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation
SKLEPINSKI, STACEY , Ratzki-Leewing, Alexandria A , Swarna, Kavya, Deng, Yihong, Neumiller, Joshua J, Galindo, Rodolfo J, Umpierrez, Guillermo E, Ross, Joseph S., Borah, B., Maron, Bradley A. , Mickelson, Mindy M, McCoy, Rozalina Grubina, Umpierrez, Guillermo E. , Sklepinski, Stacey , Ratzki-Leewing, Alexandria A , Umpierrez, Guillermo E. , Montori, Victor M , McCoy, Rozalina Grubina , Herrin, Jeph , Deng, Yihong , Polley, Eric C. , Neumiller, Joshua J. , Galindo, Rodolfo J. , Ross, Joseph S. , Brito, Juan P. , Montori, Víctor M. , Borah, Bijan J, Mickelson, Mindy M , McCoy, Rozalina G.

Mayo Clinic

BMJ Open Diabetes Research & Care | February 27, 2026 | Volume: 14 | Issue: 1 | Pages: e005646

10.1136/bmjdrc-2025-005646 | PMID 41760122 Get It

Introduction To examine within-class sulfonylurea safety, we compared risks of major adverse cardiovascular events (MACE) and severe hypoglycemia among adults with type 2 diabetes (T2D) and moderate cardiovascular risk following sulfonylurea initiation. Research design and methods We conducted a target trial emulation including adults ≥21 years old with T2D and moderate cardiovascular risk who initiated glimepiride, glipizide or glyburide between 2014 and 2021, using claims data from Optum Labs Data Warehouse and the Medicare fee-for-service 100% sample. Study outcomes were MACE (primary), expanded MACE and its components and emergency department or hospital encounters for hypoglycemia, ascertained during follow-up through 2022. Inverse probability of treatment weighting (IPTW) was applied using propensity scores estimated using the super learner ensemble, and outcomes were examined using IPTW Cox proportional hazards models. Results The weighted study cohort comprised 314 699 patients (mean age 66.9 years, 52.0% men, 76.6% non-Hispanic white). At 1 year, MACE was experienced by 2.5%, 2.7% and 2.8% of patients starting glimepiride, glipizide and glyburide, respectively. Compared with glimepiride, glyburide and glipizide were associated with higher risk of MACE (HR 1.10, 95% CI 1.05 to 1.16 for glyburide; HR 1.05, 95% CI 1.03 to 1.07 for glipizide). At 1 year, severe hypoglycemia was experienced by 0.3%, 0.3% and 0.4% of patients starting glimepiride, glipizide and glyburide, respectively. Glyburide was associated with a greater risk of severe hypoglycemia compared with glipizide (HR 1.43, 95% CI 1.23 to 1.65), while glipizide was associated with a lower risk compared with glimepiride (HR 0.82, 95% CI 0.77 to 0.87). Conclusions Among adults with T2D and moderate cardiovascular risk, glimepiride was associated with lowest risk of MACE and glipizide with lowest risk of severe hypoglycemia. These results can help inform treatment selection if sulfonylureas are used for glucose-lowering.